Get the Stockscreener App
0.648
4.47%
0.0277
After Hours:
.65
0.002
+0.31%
Bolt Biotherapeutics Inc stock is traded at $0.648, with a volume of 136.47K.
It is up +4.47% in the last 24 hours and down -4.37% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$0.6203
Open:
$0.6161
24h Volume:
136.47K
Relative Volume:
0.79
Market Cap:
$24.44M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-0.3176
EPS:
-2.04
Net Cash Flow:
$-69.73M
1W Performance:
+3.68%
1M Performance:
-4.37%
6M Performance:
-53.71%
1Y Performance:
-37.69%
1-Day Range:
$0.6161
$0.66
1-Week Range:
$0.545
$0.66
52-Week Range:
$0.545
$1.56
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 14.2% in September - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.61 - Investing.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short Interest - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.65 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.65 - Investing.com
Bolt Biotherapeutics Announces Changes to its Board of Directors - ForexTV.com
Bolt Biotherapeutics reshuffles board, appoints new chair By Investing.com - Investing.com Canada
Bolt Biotherapeutics reshuffles board, appoints new director - Investing.com
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment - TipRanks
Bolt Biotherapeutics Announces Changes to its Board of Directors - Yahoo Finance
Deadline on Sept. 3rd coming up in Lawsuit for Investors in shares of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) - openPR
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesBOLT - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the - EIN News
BOLT Investors Have the Opportunity to Lead Bolt - GlobeNewswire
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT - GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - The Malaysian Reserve
BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - Morningstar
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - GlobeNewswire Inc.
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - GlobeNewswire Inc.
BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
BOLT FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, - GlobeNewswire
BOLT FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT - GlobeNewswire Inc.
Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - Newswire
Bolt Biotherapeutics to Participate in Upcoming September Conferences - StockTitan
AI Stocks Boom Is at Risk. Why Broadcom Earnings Are Make or Break and 5 Other Things to Know Today. - Barron's
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - Marketscreener.com
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bolt - GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT - GlobeNewswire Inc.
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - Marketscreener.com
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - Morningstar
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt - GlobeNewswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT - ForexTV.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - Marketscreener.com
NASDAQ: BOLT Lawsuit Alert: Investors Who Lost Money With Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Should Contact the Shareholders Foundation - AccessWire
NASDAQ: BOLT Lawsuit Alert: Investors Who Lost Money With Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Should Contact the Shareholders Foundation - Newswire
BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz & Grossman, LLC Today! - AccessWire
Bolt Biotherapeutics (FRA:6LP) Enterprise Value : €-25.84 Mil (As of Aug. 19, 2024) - GuruFocus.com
Bolt Biotherapeutics (FRA:6LP) 9-Day RSI : 36.07 (As of Aug. 18, 2024) - GuruFocus.com
BOLT (Bolt Biotherapeutics) Market Cap : $26.46 Mil (As of Aug. 18, 2024) - GuruFocus.com
BOLT (Bolt Biotherapeutics) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
Bolt Biotherapeutics (NASDAQ:BOLT) Rating Reiterated by HC Wainwright - Defense World
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Bolt - GlobeNewswire
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):